ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

Director CMC Regulatory Affairs at Recursion - ApplyBlast

Director CMC Regulatory Affairs

Recursion

3 months ago

3.4 on Glassdoor

London, England, United Kingdom

Hybrid

Full Time

Director

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

The Director CMC Regulatory Affairs will lead the development and implementation of CMC regulatory strategy for small‑molecule investigational drugs across global Phase 1‑3 trials and marketing applications. The role involves influencing regulatory strategy, managing submission documents, delivering high‑quality US, EU and ROW regulatory submissions, and supporting cross‑functional teams with risk mitigation and compliance.

Responsibilities

Lead development and implementation of CMC regulatory strategy for small molecule drugs
Influence regulatory strategy across development programs and provide guidance on US, EU, and ROW requirements
Deliver high‑quality regulatory submissions and manage agency interactions

Skills

Qualifications

BA/BS in relevant technical disciplineMS in relevant technical disciplinePhD in relevant technical disciplineRAC certification

About Recursion

recursion.com

Headquarters

Salt Lake City, Utah, United States

Company Size

501-1000 employees

Founded

2013

View Profile

Recursion is a TechBio company that combines high-throughput experimental biology, automated imaging, and machine learning to decode biology and accelerate drug discovery. Its platform integrates large-scale biological datasets, AI models, and laboratory automation to identify and advance therapeutic candidates across multiple modalities and disease areas. Recursion develops an internal pipeline of programs and partners with biopharma and investors to translate discoveries into clinical-stage medicines. The company emphasizes a platform-first, scalable approach to make drug discovery faster, more reproducible, and more data-driven.